Swedish osteoporosis care

Archives of Osteoporosis

Volumn 10, Issue 1, 2015, Pages

  Jonsson, Emma ^a   Eriksson, Daniel ^a   Åkesson, Kristina ^b   Ljunggren, Östen ^c   Salomonsson, Stina ^d,e   Borgström, Fredrik ^a,d   Ström, Oskar ^a,d  

^a Quantify Research   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Merck Sharp Dohme (Sweden)   (Sweden)

Author keywords

Fracture; Osteoporosis; Sweden; Treatment patterns

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; CALCIUM; DENOSUMAB; ETIDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; FRAGILITY FRACTURE; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; MALE; MORTALITY; ORGANIZATION AND MANAGEMENT; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SECONDARY PREVENTION; SEX DIFFERENCE; SWEDISH CITIZEN; TIME TO TREATMENT; TREATMENT DURATION; CAUCASIAN; FRACTURES, BONE; HEALTH CARE DELIVERY; MIDDLE AGED; SWEDEN; VERY ELDERLY;

AGED, 80 AND OVER; DELIVERY OF HEALTH CARE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OUTCOME ASSESSMENT (HEALTH CARE); SECONDARY PREVENTION; SWEDEN;

EID: 84938904000     PISSN: 18623522     EISSN: 18623514     Source Type: Journal    
DOI: 10.1007/s11657-015-0222-7     Document Type: Article

References (61)

1. Giangregorio L et al (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35(5):293–305
2. SKL och Socialstyrelsen (2012) Öppna Jämförelser av hälso- och sjukvårdens kvalitet och effektivitet
3. Strom O et al (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6(1-2):59–155
4. Kanis JA et al (2013) SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 8(1-2):144
5. Elliot-Gibson V et al (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15(10):767–78
6. SKL och Socialstyrelsen (2013) Öppna Jämförelser 2013-Läkemedelsbehandlingar-Jämförelser mellan landsting
7. SBU (2003) Osteoporos—prevention, diagnostik och behandling. (165/1, 165/2)
8. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4(6):368–81
9. Melton LJ 3rd (2001) The prevalence of osteoporosis: gender and racial comparison. Calcif Tissue Int 69(4):179–81
10. Kanis JA et al (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27(5):585–90
11. Statistiska Centralbyrån (SCB). 2014-02-21.
12. Olszynski WP et al (2004) Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 26(1):15–28
13. Cooper C et al (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7(2):221–7
14. Hasserius R et al (2005) Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly—a 12- and 22-year follow-up of 257 patients. Calcif Tissue Int 76(4):235–42
15. Barrett JA, Baron JA, Beach ML (2003) Mortality and pulmonary embolism after fracture in the elderly. Osteoporos Int 14(11):889–94
16. Jonsson B et al (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967–82
17. Jalava T et al (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18(7):1254–60
18. RIKSHÖFT (2012) Årsrapport 2012
19. Borgstrom F et al (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17(5):637–50
20. Marsh D et al (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22(7):2051–65
21. Gillespie LD et al (2012) Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 9:CD007146
22. Jarvinen TL et al (2008) Shifting the focus in fracture prevention from osteoporosis to falls. BMJ 336(7636):124–6
23. Socialstyrelsen (2012) Nationella riktlinjer för rörelseorganens sjukdomar
24. Marie PJ (2006) Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol 18(Suppl 1):S11–5
25. Tandvårds- och läkemedelsverket (www.TLV.se). 2013-12-19]
26. SKL och Socialstyrelsen (2013) Öppna Jämförelser av hälso- och sjukvårdens kvalitet och effektivitet
27. McLellan AR et al (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22(7):2083–98
28. Kanis JA, WHO Scientific Group Technical Report (2007) Assessment of osteoporosis at the primary health care level: University of Sheffield
29. Strom O et al (2010) FRAX and its applications in health economics—cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47(2):430–7
30. Kanis JA, Reginster JY (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women—what is the current message for clinical practice? Pol Arch Med Wewn 118(10):538–40
31. Hernlund E et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8(1-2):136
32. Kanis JA et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57
33. Kanis JA et al (2014) Worldwide uptake of FRAX. Arch Osteoporos 9(1):166
34. Pye SR et al (2003) Frequency and causes of osteoporosis in men. Rheumatology (Oxford) 42(6):811–2
35. Geusens P et al (2008) Impact of systematic implementation of a clinical case finding strategy on diagnosis and therapy of postmenopausal osteoporosis. J Bone Miner Res 23(6):812–8
36. Kanis JA et al (2009) How to decide who to treat. Best Pract Res Clin Rheumatol 23(6):711–26
37. SKL och Socialstyrelsen (2011) Öppna Jämförelser av hälso- och sjukvårdens kvalitet och effektivitet
38. Ettinger B, Chidambaran P, Pressman A (2001) Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 7(6):597–605
39. Chami G et al (2006) Are osteoporotic fractures being adequately investigated? A questionnaire of GP & orthopaedic surgeons. BMC Fam Pract 7:7
40. Feldstein AC et al (2008) Harnessing stakeholder perspectives to improve the care of osteoporosis after a fracture. Osteoporos Int 19(11):1527–40
41. (IOF), I.O.F (2012) Capture the fracture: a global campaign to break the fragility fracture cycle: http://www.iofbonehealth.org/
42. Majumdar SR et al (2009) Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial. Arch Intern Med 169(1):25–31
43. Sander B et al (2008) A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs. J Bone Joint Surg Am 90(6):1197–205
44. Kanis JA et al (2005) Intervention thresholds for osteoporosis in the UK. Bone 36(1):22–32
45. Kanis JA et al (2012) FRAX((R)) with and without bone mineral density. Calcif Tissue Int 90(1):1–13
46. Klotzbuecher CM et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721–39
47. Kanis JA et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19(6):893–9
48. Strom O et al (2010) Cost-effectiveness of balloon kyphoplasty in patients with symptomatic vertebral compression fractures in a UK setting. Osteoporos Int 21(9):1599–608
49. Socialstyrelsen (2012) Nationella riktlinjer för rörelseorganens sjukdomar- Vetenskapligt underlag
50. Johnell O et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15(3):175–9
51. Boonen S et al (2012) Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. J Bone Miner Res 27(5):963–74
52. De Geest S, Sabate E (2003) Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs 2(4):323
53. Haynes RB, McDonald HP, Garg AX (2002) Helping patients follow prescribed treatment: clinical applications. JAMA 288(22):2880–3
54. Landfeldt E et al (2012) Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433–43
55. Silverman SL, Gold DT (2008) Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 10(2):118–22
56. Landfeldt E, Lundkvist J, Strom O (2011) The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 48(2):380–8
57. Diez-Perez A et al (2012) Treatment failure in osteoporosis. Osteoporos Int 23(12):2769–74
58. Gleeson T et al (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20(12):2127–34
59. Socialstyrelsen (2011) Ojämna villkor för hälsa och vård- Jämlikhetsperspektiv på hälso och sjukvården: http://www.socialstyrelsen.se/publikationer2011/2011-12-30
60. Socialstyrelsen och SKL (2009) Mot en effektivare kunskapsstyrning. Kartläggning och analys av nationellt och regionalt stöd före en evidensbaserad praktik i hälso- och sjukvården
61. Fernler K (2012) Kunskapsstyrning för ledning och policyarbete